213 related articles for article (PubMed ID: 11361387)
1. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
DePalma L
Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
[No Abstract] [Full Text] [Related]
2. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
Barrett N; Eder G; Dorner F
Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
[TBL] [Abstract][Full Text] [Related]
3. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
[No Abstract] [Full Text] [Related]
4. Current progress in HIV vaccines.
Westblom TU; Belshe RB; Gorse GJ
Mo Med; 1991 Nov; 88(11):762-5. PubMed ID: 1805131
[No Abstract] [Full Text] [Related]
5. Clinical trials of AIDS vaccines in seronegative volunteers: vectors and combinations.
Graham BS
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1327-8. PubMed ID: 1466951
[No Abstract] [Full Text] [Related]
6. Current approaches to vaccination against human immunodeficiency viruses.
Gluckman JC; Yagello M; Bahraoui E; Girard M
Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790
[No Abstract] [Full Text] [Related]
7. AIDS vaccine boosts immunity in HIV patients.
RN; 1991 Oct; 54(10):103. PubMed ID: 1925340
[No Abstract] [Full Text] [Related]
8. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
Parry C; McLain L; Dimmock NJ
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
[TBL] [Abstract][Full Text] [Related]
9. Properties of an HIV 'vaccine'.
Wahren B; Sandström E; Wigzell H
Nature; 1993 Apr; 362(6420):505; author reply 505-6. PubMed ID: 8464491
[No Abstract] [Full Text] [Related]
10. Which gp160 vaccine?
Moore J; Lewis GK; Robinson J
Nature; 1993 Feb; 361(6412):503. PubMed ID: 7679205
[No Abstract] [Full Text] [Related]
11. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
Pincus SH; Messer KG; Hu SL
J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
[TBL] [Abstract][Full Text] [Related]
12. Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Patel GB; Newman FK; Mandava M; Belshe RB
Vaccine; 1995 Sep; 13(13):1170-9. PubMed ID: 8578800
[TBL] [Abstract][Full Text] [Related]
13. Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins.
Rovinski B; Rodrigues L; Cao SX; Yao FL; McGuinness U; Sia C; Cates G; Zolla-Pazner S; Karwowska S; Matthews TJ
AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1187-95. PubMed ID: 8573374
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Rogers JH; Perry JE; Newman FK; Frey SE; Patel GB; Belshe RB
Vaccine; 1995 Feb; 13(2):209-14. PubMed ID: 7625118
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with gp160 in HIV.
Oyaizu N; Chirmule N; Pahwa S
N Engl J Med; 1992 Jan; 326(5):347; author reply 348. PubMed ID: 1728747
[No Abstract] [Full Text] [Related]
16. Vaccination with gp160 in HIV.
Stanberry LR; Bernstein DI; Myers MG
N Engl J Med; 1992 Jan; 326(5):347-8. PubMed ID: 1728748
[No Abstract] [Full Text] [Related]
17. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Schwartz DH; Graham BS; Matthews TJ; Stablein DM; Frey SE; Belshe RB; Clements ML; Wright PF; Eibl M
Clin Exp Immunol; 1994 Nov; 98(2):178-84. PubMed ID: 7955519
[TBL] [Abstract][Full Text] [Related]
18. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
19. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
McBurney SP; Young KR; Ross TM
Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160.
Hu SL; Klaniecki J; Dykers T; Sridhar P; Travis BM
AIDS Res Hum Retroviruses; 1991 Jul; 7(7):615-20. PubMed ID: 1768463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]